포도막염 치료 시장 규모, 점유율 및 성장 분석 : 질환 유형별, 치료 유형별, 원인별, 투여 경로별, 유통 채널별, 적응증별, 지역별 - 업계 예측(2026-2033년)

Global Uveitis Treatment Market size was valued at USD 808.79 Million in 2024 and is poised to grow from USD 862.98 Million in 2025 to USD 1449.82 Million by 2033, growing at a CAGR of 6.7% during the forecast period (2026-2033).

The ophthalmology market is witnessing significant momentum fueled by heightened research and development activities, particularly in uveitis treatment. Increasingly, clinical trials are focusing on eye inflammation, especially for challenging cases of refractory posterior and intermediate uveitis. Numerous phase III trials are assessing the effectiveness of innovative therapies, including mycophenolate mofetil and methotrexate, as alternatives to conventional corticosteroids for noninfectious uveitis. Furthermore, substantial advancements in biological drug development have broadened the therapeutic landscape for eye inflammation disorders, meeting the rising demand for effective treatment options. This convergence of innovation and clinical inquiry is propelling market expansion, as stakeholders seek more effective solutions to address the complexities of uveitis management globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Uveitis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Uveitis Treatment Market Segments Analysis

Global Uveitis Treatment Market is segmented by Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication and region. Based on Disease Type, the market is segmented into Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis and Panuveitis. Based on Treatment Type, the market is segmented into Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungal and Analgesics. Based on Cause, the market is segmented into Infectious and Non-infectious. Based on Route of Administration, the market is segmented into Topical, Systemic, Injectable and Intravitreal. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on Indication, the market is segmented into Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis and Panuveitis. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Uveitis Treatment Market

The global uveitis treatment market is significantly propelled by the increasing incidence and prevalence of uveitis across various regions. This surge can be attributed to a range of contributing factors, including a rise in autoimmune diseases, infections, and inflammatory disorders that affect numerous individuals. As more people are diagnosed with uveitis, the demand for effective treatment options escalates, creating ample opportunities for market growth. Additionally, heightened awareness and improved diagnostic capabilities further amplify the visibility of uveitis cases, fostering advancements in therapeutic solutions. Overall, the escalating health challenges associated with uveitis serve as a vital impetus for the ongoing development of treatment strategies.

Restraints in the Global Uveitis Treatment Market

A significant restraint in the global uveitis treatment market is the high cost associated with advanced therapies and medications. Innovative treatments, including biologics and targeted therapies, can be prohibitively expensive, limiting accessibility for a substantial portion of patients, particularly in low-income regions. Additionally, the lengthy and rigorous approval processes for new therapies can hinder market entry and slow the availability of potentially effective treatments. Moreover, the complexity of uveitis, with its varied underlying causes, complicates diagnosis and personalized treatment approaches, making it challenging to establish standardized treatment protocols widely accepted across different healthcare systems.

Market Trends of the Global Uveitis Treatment Market

The Global Uveitis Treatment market is witnessing a dynamic shift characterized by significant trends aimed at enhancing patient care and treatment outcomes. A notable focus is on innovative, targeted therapies, including biologics and immunomodulatory drugs, which are designed to improve efficacy and address inflammation more effectively. The adoption of sustained-release drug delivery systems, such as intravitreal implants, is also gaining traction, enabling longer drug release and minimizing injection frequency. Moreover, personalized medicine is on the rise, leveraging genetic and molecular profiling to customize treatment plans. Collaborations between pharmaceutical companies and research institutions are intensifying, driving the development of novel therapies, while advancements in technologies such as artificial intelligence and telemedicine are facilitating better patient management and remote monitoring of uveitis.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Uveitis Treatment Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Anterior Uveitis
• Posterior Uveitis
• Intermediate Uveitis
• Panuveitis

Global Uveitis Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Corticosteroids
• Immunosuppressant
• Monoclonal Antibodies
• Cycloplegic Agents
• Antibiotics
• Antivirals
• Antifungal
• Analgesics

Global Uveitis Treatment Market Size by Cause & CAGR (2026-2033)

• Market Overview
• Infectious
• Non-infectious

Global Uveitis Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Topical
• Systemic
• Injectable
• Intravitreal

Global Uveitis Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Uveitis Treatment Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Anterior Uveitis
• Intermediate Uveitis
• Posterior Uveitis
• Panuveitis

Global Uveitis Treatment Market Size & CAGR (2026-2033)

• North America (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
  • US
  • Canada
• Europe (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyePoint Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alimera Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eyegate Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Therapeutics Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galapagos NV (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tarsier Pharma Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TopiVert Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations